The aim of this study was to evaluate the effects of probiotic VSL#3 on glomerular filtration rate (GFR) in dogs affected by chronic kidney disease (CKD). The treatment group (n = 30) received prescription renal diet and probiotic VSL#3 (112 to 225 × 109 lyophilized bacteria per 10 kg body weight, PO, q24h for 2 months); the control group (n = 30) received prescription renal diet and standard therapy. All dogs underwent GFR measurement at the beginning of the study (T0) and were re-evaluated by GFR measurement after 2 months (T1). The GFR was significantly higher (P = 0.0001) in the treatment group compared to the control group at T1. In the treatment group, the GFR was significantly higher (P = 0.0008) at T1 compared to T0. In the control group, the GFR was significantly lower (P = 0.001) at T1 compared to T0. VSL#3 supplementation seemed to be efficient in reducing deterioration of GFR over time in dogs affected by CKD.

Effects of probiotic VSL#3 on glomerular filtration rate in dogs affected by chronic kidney disease: a pilot study

Lippi I
;
MARCHETTI, VERONICA;GUIDI, GRAZIA
2017-01-01

Abstract

The aim of this study was to evaluate the effects of probiotic VSL#3 on glomerular filtration rate (GFR) in dogs affected by chronic kidney disease (CKD). The treatment group (n = 30) received prescription renal diet and probiotic VSL#3 (112 to 225 × 109 lyophilized bacteria per 10 kg body weight, PO, q24h for 2 months); the control group (n = 30) received prescription renal diet and standard therapy. All dogs underwent GFR measurement at the beginning of the study (T0) and were re-evaluated by GFR measurement after 2 months (T1). The GFR was significantly higher (P = 0.0001) in the treatment group compared to the control group at T1. In the treatment group, the GFR was significantly higher (P = 0.0008) at T1 compared to T0. In the control group, the GFR was significantly lower (P = 0.001) at T1 compared to T0. VSL#3 supplementation seemed to be efficient in reducing deterioration of GFR over time in dogs affected by CKD.
2017
Lippi, I; Perondi, F; Marchetti, Veronica; Ceccherini, G; Guidi, Grazia
File in questo prodotto:
File Dimensione Formato  
VSL revised Apr 2017.pdf

accesso aperto

Tipologia: Documento in Post-print
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 368.8 kB
Formato Adobe PDF
368.8 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11568/860253
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 11
social impact